Emmaus Life Sciences, Inc. (EMMA)
USD 0.02
(-12.28%)
USD 0.02
(-12.28%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.71 Million USD | 10.25% |
| 2022 | 22.38 Million USD | -4.43% |
| 2021 | 23.42 Million USD | 11.81% |
| 2020 | 20.95 Million USD | -19.94% |
| 2019 | 26.17 Million USD | 143.83% |
| 2018 | 10.73 Million USD | 49.51% |
| 2017 | 7.17 Million USD | 86.63% |
| 2016 | 3.84 Million USD | 39.79% |
| 2015 | 2.75 Million USD | -29.06% |
| 2014 | 3.87 Million USD | -7.4% |
| 2013 | 4.18 Million USD | -12.53% |
| 2012 | 4.78 Million USD | -25.5% |
| 2011 | 6.42 Million USD | -8.28% |
| 2010 | 7 Million USD | 0.98% |
| 2009 | 6.94 Million USD | 14.07% |
| 2008 | 6.08 Million USD | 82.07% |
| 2007 | 3.34 Million USD | 702.91% |
| 2006 | 416.2 Thousand USD | 1356.35% |
| 2005 | 28.57 Thousand USD | -89.05% |
| 2004 | 261.08 Thousand USD | 80.63% |
| 2003 | 144.54 Thousand USD | 747.34% |
| 2002 | 17.05 Thousand USD | 4.01% |
| 2001 | 16.4 Thousand USD | 5.45% |
| 2000 | 15.55 Thousand USD | -22.23% |
| 1999 | 19.99 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.98 Million USD | -9.64% |
| 2024 Q2 | 4.55 Million USD | -8.72% |
| 2023 Q4 | 5.52 Million USD | 15.5% |
| 2023 Q2 | 6.92 Million USD | -7.53% |
| 2023 Q1 | 7.48 Million USD | 11.73% |
| 2023 FY | 24.68 Million USD | 10.25% |
| 2023 Q3 | 4.78 Million USD | -30.97% |
| 2022 Q3 | 5.05 Million USD | -5.1% |
| 2022 Q4 | 6.7 Million USD | 32.5% |
| 2022 FY | 22.38 Million USD | -4.43% |
| 2022 Q1 | 5.29 Million USD | -11.51% |
| 2022 Q2 | 5.33 Million USD | 0.68% |
| 2021 Q3 | 5.35 Million USD | -4.02% |
| 2021 Q2 | 5.57 Million USD | -14.4% |
| 2021 Q1 | 6.51 Million USD | 28.96% |
| 2021 FY | 23.42 Million USD | 11.81% |
| 2021 Q4 | 5.98 Million USD | 11.81% |
| 2020 Q2 | 5.44 Million USD | 2.0% |
| 2020 Q1 | 5.34 Million USD | 21.88% |
| 2020 Q3 | 5.1 Million USD | -6.24% |
| 2020 Q4 | 5.05 Million USD | -1.14% |
| 2020 FY | 20.95 Million USD | -19.94% |
| 2019 FY | 26.17 Million USD | 143.83% |
| 2019 Q2 | 2.82 Million USD | -0.91% |
| 2019 Q3 | 9.81 Million USD | 247.77% |
| 2019 Q1 | 2.84 Million USD | 0.15% |
| 2019 Q4 | 4.38 Million USD | -55.34% |
| 2018 Q4 | 2.84 Million USD | 36.39% |
| 2018 Q2 | 3.06 Million USD | 9.53% |
| 2018 Q1 | 2.79 Million USD | 0.06% |
| 2018 Q3 | 2.08 Million USD | -31.89% |
| 2018 FY | 10.73 Million USD | 49.51% |
| 2017 Q3 | 2.69 Million USD | 70.91% |
| 2017 Q1 | 1.44 Million USD | -0.43% |
| 2017 Q2 | 1.57 Million USD | 9.0% |
| 2017 Q4 | 2.79 Million USD | 3.52% |
| 2017 FY | 7.17 Million USD | 86.63% |
| 2016 Q1 | 709.3 Thousand USD | 9.73% |
| 2016 Q4 | 1.45 Million USD | -12.39% |
| 2016 Q3 | 1.66 Million USD | 100.3% |
| 2016 FY | 3.84 Million USD | 39.79% |
| 2016 Q2 | 828.8 Thousand USD | 16.85% |
| 2015 Q3 | 567.4 Thousand USD | -3.03% |
| 2015 Q1 | 798.3 Thousand USD | -0.31% |
| 2015 FY | 2.75 Million USD | -29.06% |
| 2015 Q4 | 646.4 Thousand USD | 13.92% |
| 2015 Q2 | 585.1 Thousand USD | -26.71% |
| 2014 FY | 3.87 Million USD | -7.4% |
| 2014 Q3 | 921.3 Thousand USD | -11.03% |
| 2014 Q4 | 800.8 Thousand USD | -13.08% |
| 2014 Q1 | 950.6 Thousand USD | -2.13% |
| 2014 Q2 | 1.03 Million USD | 8.93% |
| 2013 Q1 | 1.11 Million USD | 60.73% |
| 2013 FY | 4.18 Million USD | -12.53% |
| 2013 Q3 | 1.2 Million USD | 3.6% |
| 2013 Q4 | 971.3 Thousand USD | -19.63% |
| 2013 Q2 | 1.16 Million USD | 4.32% |
| 2012 Q4 | 695.7 Thousand USD | 231.6% |
| 2012 Q2 | 1.4 Million USD | -11.67% |
| 2012 FY | 4.78 Million USD | -25.5% |
| 2012 Q1 | 1.59 Million USD | 1.44% |
| 2012 Q3 | 209.8 Thousand USD | -85.12% |
| 2011 Q2 | 1.6 Million USD | -3.21% |
| 2011 FY | 6.42 Million USD | -8.28% |
| 2011 Q4 | 1.57 Million USD | 4.86% |
| 2011 Q1 | 1.66 Million USD | 0.39% |
| 2011 Q3 | 1.5 Million USD | -6.74% |
| 2010 Q2 | 1.58 Million USD | 3.57% |
| 2010 Q1 | 1.53 Million USD | -22.31% |
| 2010 FY | 7 Million USD | 0.98% |
| 2010 Q3 | 1.92 Million USD | 21.15% |
| 2010 Q4 | 1.65 Million USD | -13.8% |
| 2009 Q3 | 2.24 Million USD | 48.63% |
| 2009 Q4 | 1.97 Million USD | -12.17% |
| 2009 FY | 6.94 Million USD | 14.07% |
| 2009 Q1 | 1.6 Million USD | 2.09% |
| 2009 Q2 | 1.5 Million USD | -5.89% |
| 2008 Q2 | 1.8 Million USD | 20.87% |
| 2008 Q1 | 1.49 Million USD | 38.07% |
| 2008 Q4 | 1.57 Million USD | -7.56% |
| 2008 FY | 6.08 Million USD | 82.07% |
| 2008 Q3 | 1.69 Million USD | -5.94% |
| 2007 FY | 3.34 Million USD | 702.91% |
| 2007 Q4 | 1.08 Million USD | -34.38% |
| 2007 Q3 | 1.65 Million USD | 179.9% |
| 2007 Q1 | 1.37 Million USD | 2268.63% |
| 2007 Q2 | 589.5 Thousand USD | -57.08% |
| 2006 Q4 | 57.98 Thousand USD | -54.61% |
| 2006 Q3 | 127.73 Thousand USD | -43.47% |
| 2006 Q2 | 225.96 Thousand USD | 4893.68% |
| 2006 Q1 | 4525.00 USD | -68.98% |
| 2006 FY | 416.2 Thousand USD | 1356.35% |
| 2005 Q2 | -942.00 USD | -110.02% |
| 2005 FY | 28.57 Thousand USD | -89.05% |
| 2005 Q4 | 14.58 Thousand USD | 163.72% |
| 2005 Q3 | 5532.00 USD | 687.26% |
| 2005 Q1 | 9400.00 USD | -91.08% |
| 2004 Q4 | 105.33 Thousand USD | -26.6% |
| 2004 FY | 261.08 Thousand USD | 80.63% |
| 2004 Q1 | 2173.00 USD | -60.78% |
| 2004 Q3 | 143.51 Thousand USD | 208.85% |
| 2004 Q2 | 46.46 Thousand USD | 2038.33% |
| 2003 FY | 144.54 Thousand USD | 747.34% |
| 2003 Q1 | 3628.00 USD | -27.15% |
| 2003 Q4 | 5541.00 USD | -90.56% |
| 2003 Q3 | 58.67 Thousand USD | -23.5% |
| 2003 Q2 | 76.7 Thousand USD | 2014.11% |
| 2002 Q1 | 5184.00 USD | -13.67% |
| 2002 FY | 17.05 Thousand USD | 4.01% |
| 2002 Q4 | 4980.00 USD | 65.34% |
| 2002 Q3 | 3012.00 USD | -22.39% |
| 2002 Q2 | 3881.00 USD | -25.14% |
| 2001 Q2 | 2476.00 USD | -61.62% |
| 2001 FY | 16.4 Thousand USD | 5.45% |
| 2001 Q1 | 6452.00 USD | -35.48% |
| 2001 Q4 | 6005.00 USD | 304.38% |
| 2001 Q3 | 1485.00 USD | -40.02% |
| 2000 Q4 | 10 Thousand USD | 0.0% |
| 2000 Q2 | 10 Thousand USD | 0.0% |
| 2000 FY | 15.55 Thousand USD | -22.23% |
| 2000 Q1 | - USD | -100.0% |
| 2000 Q3 | - USD | -100.0% |
| 1999 FY | 19.99 Thousand USD | 0.0% |
| 1999 Q4 | 10 Thousand USD | 0.0% |
| 1999 Q3 | - USD | -100.0% |
| 1999 Q2 | 10 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1750.713% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -390.178% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 16.371% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1008.356% |
| Rebus Holdings, Inc. | 664 Thousand USD | -3622.139% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 33.661% |
| Qrons Inc. | 643.67 Thousand USD | -3739.659% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -6244.239% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 56.972% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -5848.556% |
| Skye Bioscience, Inc. | 13.54 Million USD | -82.432% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 71.522% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -402.551% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -9343.082% |
| SQZ Biotechnologies Company | 85.61 Million USD | 71.134% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -747.497% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1545.583% |
| Mesoblast Limited | 5.9 Million USD | -318.756% |
| Marizyme, Inc. | 19.23 Million USD | -28.457% |
| Genus plc | 147.7 Million USD | 83.267% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -181.517% |
| Pharming Group N.V. | 225.49 Million USD | 89.039% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1106.372% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1742.279% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -196.378% |
| ContraFect Corporation | 56.88 Million USD | 56.556% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -460.6% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1571.342% |
| IMV Inc. | 37.7 Million USD | 34.459% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -785.729% |
| MultiCell Technologies, Inc. | 567.42 USD | -4355580.096% |
| ONE Bio Corp. | 6.44 Million USD | -283.541% |
| Accustem Sciences Inc. | 3.74 Million USD | -559.697% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 71.243% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -4546.009% |
| Q BioMed Inc. | 3.43 Million USD | -619.164% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -840.62% |
| Biomind Labs Inc. | 994.18 Thousand USD | -2385.963% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 75.118% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1304.518% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -267.891% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1225.649% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 98960.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -54.37% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1246.797% |
| GB Sciences, Inc. | 1.42 Million USD | -1639.869% |
| Alpha Cognition Inc. | 9.7 Million USD | -154.647% |
| HST Global, Inc. | 140.9 Thousand USD | -17439.938% |
| CSL Limited | 3.44 Billion USD | 99.283% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2097.065% |
| Halberd Corporation | 74.84 Thousand USD | -32922.902% |
| Enzolytics Inc. | 2.17 Million USD | -1033.972% |
| Agentix Corp. | 1.37 Million USD | -1701.705% |
| Resverlogix Corp. | 12.71 Million USD | -94.423% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -576.992% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.388% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2267.337% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -927.679% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1464.879% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -625.849% |
| AVAX Technologies, Inc. | 7.31 Million USD | -238.086% |
| Zenith Capital Corp. | 8.94 Million USD | -176.361% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.005% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -141769.009% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -906.591% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -14310.322% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1186.632% |
| Kadimastem Ltd | 2.41 Million USD | -925.471% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1153.275% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -127.432% |
| BioStem Technologies, Inc. | 22.97 Million USD | -7.574% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -13518.205% |
| LadRx Corporation | 3.81 Million USD | -548.383% |
| Cell Source, Inc. | 4.32 Million USD | -471.399% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2576.203% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -2576.203% |
| NovAccess Global Inc. | 2.46 Million USD | -901.921% |
| Affymax, Inc. | 39.38 Million USD | 37.249% |
| Itoco Inc. | 919.14 Thousand USD | -2588.918% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -483.119% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2108.668% |
| Mobile Lads Corp. | 554.54 Thousand USD | -4356.799% |
| CytoDyn Inc. | 18.05 Million USD | -36.865% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -98096.194% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -11130.109% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1640.748% |
| SYBLEU INC | 160.87 Thousand USD | -15262.764% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1260.718% |
| International Stem Cell Corporation | 5.27 Million USD | -368.886% |
| Bioxytran, Inc. | 3.82 Million USD | -546.965% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -46849.204% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -121391.422% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 31.851% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1427.503% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -3258.769% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -694.439% |
| Neutra Corp. | 243.82 Thousand USD | -10036.535% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -41.576% |
| PureTech Health plc | 144.59 Million USD | 82.908% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -20.62% |
| IXICO plc | 4.7 Million USD | -425.069% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -180.948% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 79.01% |
| CSL Limited | 3.89 Billion USD | 99.365% |
| Cellectis S.A. | 97.32 Million USD | 74.604% |